FEXO 120 (Tablets)
FEXO 180 (Tablets)
(and dosage form):
FEXO 120 (Tablets)
FEXO 180 (Tablets)
FEXO 120 Tablets: Each coated tablet contains 120 mg fexofenadine hydrochloride.
FEXO 180 Tablets: Each coated tablet contains 180 mg fexofenadine hydrochloride.
A 5.7.1 Antihistaminics.
Fexofenadine hydrochloride is a non-sedating selective histamine H1-receptor antagonist. It is the major active metabolite of terfenadine. The antihistaminic effect of fexofenadine starts within one hour post dose, reaches maximum effect at 6 hours and lasts for 24 hours.
Following oral administration, fexofenadine is absorbed into the body. Tmax is reached approximately 1-3 hours after administration. After a single once daily dose of 120 mg or 180 mg, mean Cmax values of approximately 427 ng/mL and 494 ng/mL, respectively, are obtained.
Fexofenadine has a volume of distribution of 5.4-5.8 L/kg body weight.
Fexofenadine does not transfer across the blood-brain barrier.
Sixty to seventy percent of fexofenadine is plasma protein bound. Studies in animals and humans reveal that fexofenadine undergoes negligible metabolism, as it is the only major molecule detected in urine and faeces.
The intestinal mucosa metabolises about 5% of the total dose, while only 0.5-1.5% of the dose undergoes hepatic biotransformation. After multiple dosing, the plasma concentration profiles of fexofenadine show a biexponential decline and a terminal elimination half-life of 11-15 hours.
Daily administration of between 40 mg and 240 mg fexofenadine shows linear single and multiple dose pharmacokinetics. Biliary excretion (faeces) seems to be the major route of elimination with up to 10% of the ingested dose being eliminated unchanged through urinary excretion.
Effect of age:
Peak plasma levels of fexofenadine are 99% greater in older subjects (> 65 years of age), compared to those observed in younger volunteers (< 65 years of age). Similar mean elimination half-lives are observed in the two age groups.
Peak plasma levels of fexofenadine were 87% and 111% greater in patients with mild (creatinine clearance 41-80 mL/min) to severe (creatinine clearance 11-40 mL/min) renal impairment, respectively. Compared to observations in normal volunteers, the mean elimination half-lives were also 59% and 72% longer, respectively, in these patient groups. In patients on dialysis (creatinine clearance <10 mL/min), peak plasma levels were 82% greater and half-life was 31% longer compared to that of normal volunteers.
FEXO 120 is indicated for the relief of seasonal allergic rhinitis (SAR) symptoms.
FEXO 180 is indicated for the relief of chronic idiopathic urticaria (CIU) symptoms.
The safety in pregnancy and lactation has not been established (see WARNINGS).
There are no studies on the safety and efficacy of FEXO in children under the age of 12 years.
Hypersensitivity to FEXO or any of its ingredients.
Data on the use in the elderly and in renally or hepatically impaired patients is limited. Use FEXO with care in these special risk groups.
FEXO is excreted in breast milk.
The ability to drive or operate machinery may be affected by FEXO.
FEXO is not metabolised in the liver. A two to three fold increase in the plasma levels of FEXO result from co-administration of FEXO with erythromycin or ketoconazole. These changes do not coincide with changes in the QT- interval and are not accompanied by any increase in adverse reactions compared to the drugs administered individually. An increase in gastrointestinal absorption together with either a decrease in biliary excretion or a decrease in gastrointestinal secretion, appears to be responsible for the increase in plasma levels of FEXO following co-administration with either erythromycin or ketoconazole.
There is no interaction between FEXO and omeprazole. However, the bioavailability of FEXO is reduced when an antacid containing aluminium and magnesium hydroxide gels is administered 15 minutes prior to FEXO.
This most likely results from binding in the gastrointestinal tract.
Therefore the administration of FEXO and aluminium and magnesium hydroxide containing antacids should be spaced two hours apart.
PREGNANCY AND LACTATION:
There is no data on the use of FEXO in pregnant women.
Do not take FEXO during pregnancy or lactation.
DOSAGE AND DIRECTIONS FOR USE:
Adults and children aged 12 years and older:
Chronic idiopathic urticaria (CIU): Take one 180 mg tablet once a day.
Seasonal allergic rhinitis (SAR): Take one 120 mg tablet once a day.
Children younger than 12 years of age:
The safety and efficacy of FEXO in children younger than 12 years has not been studied.
Special risk groups: (see WARNINGS)
Because of the increases in bioavailability and half-life, a single dose of 60 mg daily is recommended as the starting dose in patients with renal impairment.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
The following side-effects can occur:
Less Frequent: Fatigue.
Central nervous system disorders:
Frequent: Drowsiness, dizziness, headache
Less Frequent: Sleep disorders or paranoia, insomnia, nervousness.
Gastrointestinal system disorders:
Less Frequent: Dyspepsia.
Less Frequent: Chest tightness, dyspnoea, angioedema, flushing, systemic anaphylaxis, urticaria, pruritus, rash.
Respiratory system disorders:
Less Frequent: Viral infections such as cold or flu and sinusitis.
Reproductive system disorders:
Less Frequent: Dysmenorrhoea.
No cardiovascular, haematological, hepatobiliary, musculoskeletal or renal side-effects have been reported.
FEXO has no sedative effects but since a small number of individuals may experience sedation, patients should be warned of this. Each individuals response to the medication should therefore be determined prior to driving or performing complicated tasks.
The sedative effects may be enhanced by the concomitant intake of other central nervous system depressants or alcohol (see Pharmacokinetics, INTERACTIONS and WARNINGS).
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
There is limited information on FEXO overdoses. However, available data have reported drowsiness, dizziness and a dry mouth. Any unabsorbed drug should be removed by standard measures.
Haemodialysis is not an effective measure to remove FEXO from the circulation.
FEXO 120: Peach coloured, oblong, biconvex, film-coated tablets, plain on one side with a central breakline on the other.
FEXO 180: Yellow coloured, oblong, biconvex, film-coated tablets, plain on one side with a central breakline on the other.
Both strengths are packed in transparent PVC and aluminium foil blister strips with 5, 10 or 15 tablets, packed in cartons of 5, 10 or 30 tablets.
Store below 25°C. Keep the blister strips in the carton until required for use.
KEEP OUT OF REACH OF CHILDREN.
FEXO 120: A38/5.7.1/0414
FEXO 180: A38/5.7.1/0415
NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:
CIPLA MEDPRO (PTY) LTD
Rosen Heights, Pasita Street,
Rosen Park, Bellville, 7530, RSA.
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
© CIPLA MEDPRO (PTY) LTD
New addition to this site: April 2014
Source : http://www.ciplamedpro.co.za/product-catalog/otc-products/allergy/
CURRENT: January 2017
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
Information presented by Malahyde Information Systems © Copyright 1996-2017